Recently, the Spanish NMO Study Group reported that double-seronegative and AQP4-IgG-seropositive NMOSD patients had a similar clinical outcome, while those seropositive for MOG-IgG had a more favorable prognosis [169]. The gene discussed is MOG; the disease is neuromyelitis optica.